Ultra Market Research | United States Regenerative Medicine Market
United States Regenerative Medicine Market
Report ID : 607
Category : Medical-Devices
No Of Pages : 150
Published on: August 2024
Status: Published
Format :
Key Question Answer
Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major players financial performance.
Evaluate strategies adopted by major players.
Recommendations
U.S. Regenerative Medicine Market Estimated at US$ XX billion in 2023, the U.S. regenerative medicine industry is projected to reach around US$ XX billion by 2033, with a compound annual growth rate (CAGR) of XX% from 2024 to 2033. Regenerative medicine has the ability to significantly improve the treatment of aged, diseased, or traumatized tissues and organs as well as address congenital problems. Clinical and preclinical evidence point to promising results for the treatment of acute and chronic illnesses in a variety of organ systems, including skin wounds, heart problems, and several types of cancer. In contrast to existing transplantation therapies, which face significant obstacles due to severe immunological consequences and a restricted donor pool, regenerative medicine presents novel approaches that may be able to overcome these problems. The ability to treat a wide range of illnesses and enhance patient outcomes is a major factor propelling the growth of the regenerative medicine industry in the United States.
Market Overview Due to developments in an interdisciplinary discipline that combines engineering and life science concepts to enhance tissue and organ regeneration, the U.S. regenerative medicine business is expanding quickly. The field has made great strides since its founding several decades ago, including FDA-approved treatments for orthopedic and wound healing applications that are currently offered for sale. Regenerative medicine replaces or repairs damaged tissues both physically and functionally by the use of materials, de novo produced cells, and their combinations. Another intriguing strategy is to take advantage of the body's natural mending powers, which are much less developed in humans than in lower vertebrates. In order to guarantee the development and standardization of regeneration therapies, the FDA's Center for Biologics Evaluation and Research (FDA/CBER) and the Standards Coordinating Body work closely with the NIST regeneration Medicine program, further driving the market's growth.
Report Highlights By Therapeutic Category Of all the regenerative medicine specialties—which include tissue engineering, cell therapy, and gene therapy—oncology holds the most market share. These innovative methods are essential for improving our understanding of cancer biology and for treating cancer and creating complex cancer models. The main goal is to bridge the gap from bench to bedside by converting basic and laboratory research into efficient clinical treatments. The goal of the area of regenerative medicine is to improve therapeutic results and quality of life for patients by lessening their burden of illness and treatment through proper interpretation of research efforts. Because cardiovascular diseases (CVD) are becoming more common, the cardiovascular segment is expected to increase at a considerable compound annual growth rate (CAGR) over the forecast period. Ischemic heart disease (IHD) is being treated using regenerative medicine more and more, especially when it comes to using stem cells to replace damaged heart tissue. Heart function can be restored with stem cell transplantation at infarcted locations, which can produce new cardiomyocytes. Regenerative medicine is an interdisciplinary field that tries to replace, restore, or repair damaged organ parts. As such, it is an important therapeutic area to address cardiovascular health.
By Product Market was dominated by the therapeutics category, which mirrored the primary goal of regenerative medicine, which is to replace or restore organs and tissues that have been harmed by illness, trauma, aging, or birth defects as opposed to just treating symptoms with drugs and treatments. Regenerative medicine has the enormous potential to restore or replace damaged organs and tissues, as well as to normalize birth defects. Its potential to cure a wide range of medical disorders, such as cutaneous wounds, cardiovascular diseases, traumas, and some cancer treatments, is supported by strong preclinical and clinical data. The therapeutics area holds a substantial market share, which is supported by this transformational strategy. Increasing significance of stem cell banking is expected to propel the bank segment to become the fastest-growing industry over the projection period. This procedure makes it possible to cryogenically preserve stem cells in the most effective form for use in regenerative medicine down the road. Bone marrow, umbilical cord blood and tissue, and adipose tissue are important sources of useful stem cells that may be obtained from most people in a relatively simple and economical manner. Autologous stem cell banking is expected to play a major role in the advancement of personalized and regenerative medicine approaches. The best time to bank stem cells is when the donor is young and healthy, while older donors and donors with inflammatory or chronic diseases have less functional stem cells. This proactive planning in stem cell banking raises the possibility of successful regenerative medicine.
Market Dynamics Driver Advancements in Regenerative Medicine Introduction of novel, FDA-approved treatments intended to treat a range of diseases is propelling the market for regenerative medicine in the United States to record high growth. Extensive research has made it possible to develop sophisticated grafts that effectively repair tissues by controlling cell behavior through the use of scaffolding materials and cell manipulation technology. These scaffolds offer significant control over the spatial location of cells and can be carefully shaped to fit the anatomy of the patient. New approaches are being explored to improve the integration of the graft with the nervous system and vasculature of the host, mainly by seeding vascular cells and releasing growth factors under control. The immune system can be modulated to enhance the body's healing response. The creation of new cell sources for transplantation solves the earlier supply constraints on cells, which fuels the market's growth even more. Together, these developments highlight the regenerative medicine market's strong growth and revolutionary potential in the United States.
Restraints High Costs and Regulatory Hurdles A major obstacle confronting the field of regenerative medicine is the exorbitant expense of treatments, including CAR-T cell therapy, which can reach hundreds of thousands of dollars per patient. Accessibility is constrained by this financial barrier, especially for patients who lack insurance or have limited financial resources. The regulatory landscape presents formidable obstacles. The regulatory approval procedure for regenerative medicine medicines is complicated by their high level of complexity, which frequently involves the combination of multiple technologies. To ensure compliance with all applicable regulations, investors need to be aware of these regulatory obstacles and work closely with regulatory bodies and industry experts. The market for regenerative medicine in the United States has limited growth potential due to a combination of financial and regulatory obstacles.
Opportunities AI Integration Regenerative medicine is a rapidly developing area that uses cutting edge techniques including gene therapy, tissue engineering, and stem cell therapy to replace, regenerate, or repair damaged or sick tissues and organs. Artificial intelligence (AI) technology have opened up new research and development opportunities in this field. Artificial Intelligence (AI) has promise for greatly advancing and speeding up many parts of regenerative medicine research. AI learns patterns in data and applies this knowledge autonomously, enabling computers to accomplish jobs that need human intelligence. Artificial intelligence (AI) systems can enhance learning, reasoning, perception, and problem-solving skills by imitating human cognition. This can optimize intricate processes that are inherent in regenerative medicine. The potential for artificial intelligence (AI) to grow over time, learn from data and past experiences, and advance the field of regenerative medicine in the United States, spur innovation, and enhance patient outcomes is significant.
Recent Developments
• In April 2023, Mount Sinai launched the Institute for Regenerative Medicine. • In March 2024, the shift to regenerative medicine increased growth prospects for PHI. • In December 2023, Medicine by Design and CCRM launched an alliance to bolster Canada’s leading position in regenerative medicine. • In October 2023, Bayer opened its first cell therapy manufacturing facility to advance regenerative medicines on a global scale. • In January 2024, STEMCELL Technologies announced the acquisition of Propagenix Inc. • In January 2023, Zimmer Biomet announced plans to acquire Embody, Inc. • In August 2022, ElevateBio partnered with the California Institute for Regenerative Medicine to accelerate the development of regenerative medicines. • In July 2022, Mogrify and Astellas announced a collaboration to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing loss.
Key Players in the U.S. Regenerative Medicine Market AstraZeneca plc F. Hoffmann-La Roche Ltd. Integra Lifesciences Corp. Astellas Pharma, Inc. Cook Biotech, Inc. Bayer AG Pfizer, Inc. Merck KGaA Abbott Vericel Corp. Novartis AG GlaxoSmithKline (GSK)
Table of content 1. Introduction 1.1. Report Description 1.2. Research Methodology 1.2.1. Data Mining 1.2.2. Market Modeling and Forecasting 1.2.3. Data Validation 1.2.4. Industry Analysis
4. United States Regenerative Medicine Market by Product Outlook 4.1. Introduction 4.2. United States Regenerative Medicine Market Size and Growth Rate by Product Outlook (2021-2030) 4.3. Therapeutics 4.3.1. Therapeutics Market Size and Growth Rate (2019- 2030) 4.4. Primary Cell-based Therapeutics 4.4.1. Primary Cell-based Therapeutics Market Size and Growth Rate (2019- 2030) 4.5. Dermatology 4.5.1. Dermatology Market Size and Growth Rate (2021-2030) 4.6. Musculoskeletal 4.6.1. Musculoskeletal Market Size and Growth Rate (2021-2030) 4.7. Others 4.7.1. Others Market Size and Growth Rate (2021-2030)
5. United States Regenerative Medicine Market by Stem Cell & Progenitor Cell-based Therapeutics 5.1. Introduction 5.2. United States Regenerative Medicine Market Size and Growth Rate by Stem Cell & Progenitor Cell-based Therapeutics (2021-2030) 5.3. Autologous 5.3.1. Autologous Market Size and Growth Rate (2021-2030) 5.4. Allogenic 5.4.1. Allogenic Market Size and Growth Rate (2021-2030) 5.5. Others 5.5.1. Others Market Size and Growth Rate (2021-2030)
6. United States Regenerative Medicine Market by Therapeutic Category Outlook 6.1. Introduction 6.2. United States Regenerative Medicine Market Size and Growth Rate by Therapeutic Category Outlook (2021-2030) 6.3. Gene Therapies 6.3.1. Gene Therapies Market Size and Growth Rate (2021-2030) 6.4. Tools 6.4.1. Tools Market Size and Growth Rate (2021-2030) 6.5. Banks 6.5.1. Banks Market Size and Growth Rate (2021-2030) 7.1. Introduction 7.2. United States Regenerative Medicine Market Size and Growth Rate by Therapeutic Category Outlook (2021-2030) 7.3. Dermatology 7.3.1. Dermatology Market Size and Growth Rate (2021-2030) 7.4. Musculoskeletal 7.4.1. Musculoskeletal Market Size and Growth Rate (2021-2030) 7.5. Immunology & Inflammation 7.5.1. Immunology & Inflammation Market Size and Growth Rate (2021-2030)
8. Company Profiles 8.1. AstraZeneca plc 8.1.1. Business Overview 8.1.2. Service Portfolio 8.1.3. Strategic Developments 8.1.4. Financial Overview
8.2. F. Hoffmann-La Roche Ltd. 8.2.1. Business Overview 8.2.2. Service Portfolio 8.2.3. Strategic Developments 8.2.4. Financial Overview
8.3. Integra Lifesciences Corp. 8.3.1. Business Overview 8.3.2. Service Portfolio 8.3.3. Strategic Developments 8.3.4. Financial Overview
8.4. Astellas Pharma, Inc. 8.4.1. Business Overview 8.4.2. Service Portfolio 8.4.3. Strategic Developments 8.4.4. Financial Overview
8.5. Cook Biotech, Inc. 8.5.1. Business Overview 8.5.2. Service Portfolio 8.5.3. Strategic Developments 8.5.4. Financial Overview
8.6. Bayer AG 8.6.1. Business Overview 8.6.2. Service Portfolio 8.6.3. Strategic Developments 8.6.4. Financial Overview
8.7. Pfizer, Inc. 8.7.1. Business Overview 8.7.2. Service Portfolio 8.7.3. Strategic Developments 8.7.4. Financial Overview
8.8. Merck KGaA 8.8.1. Business Overview 8.8.2. Service Portfolio 8.8.3. Strategic Developments 8.8.4. Financial Overview
8.9. Abbott 8.9.1. Business Overview 8.9.2. Service Portfolio 8.9.3. Strategic Developments 8.9.4. Financial Overview
8.8. Vericel Corp. 8.8.1. Business Overview 8.8.2. Service Portfolio 8.8.3. Strategic Developments 8.8.4. Financial Overview
8.11. Novartis AG 8.11.1. Business Overview 8.11.2. Service Portfolio 8.11.3. Strategic Developments 8.11.4. Financial Overview
8.12. GlaxoSmithKline (GSK) 8.12.1. Business Overview 8.12.2. Service Portfolio 8.12.3. Strategic Developments 8.12.4. Financial Overview
11. List of Tables and Figures Table United States Regenerative Medicine Market Size and Market Share by Product Outlook (2021-2023) Table United States Regenerative Medicine Market Size and Market Share by Product Outlook (2023-2030) Figure Therapeutics Market Size and Growth Rate (2021-2030) Figure Primary Cell-based Therapeutics Market Size and Growth Rate (2021-2030) Figure Dermatology Market Size and Growth Rate (2021-2030) Figure Musculoskeletal Market Size and Growth Rate (2021-2030) Figure Others Market Size and Growth Rate (2021-2030)
Table United States Regenerative Medicine Market Size and Market Share by Stem Cell(2021-2023) Table United States Regenerative Medicine Market Size and Market Share by Stem Cell & Progenitor Cell-based Therapeutics (2023-2030) Figure Autologous Market Size and Growth Rate (2021-2030) Figure Allogenic Market Size and Growth Rate (2021-2030) Figure Others Market Size and Growth Rate (2021-2030)
Table United States Regenerative Medicine Market Size and Market Share by Cell-based Immunotherapies (2021-2023) Table United States Regenerative Medicine Market Size and Market Share by Therapeutic Category Outlook (2023-2030) Figure Gene Therapies Market Size and Growth Rate (2021-2030) Figure Tools Market Size and Growth Rate (2021-2030) Figure Banks Market Size and Growth Rate (2021-2030) Table United States Regenerative Medicine Market Size and Market Share by Therapeutic Category Outlook (2021-2023) Table United States Regenerative Medicine Market Size and Market Share by Therapeutic Category Outlook (2023-2030) Figure Dermatology Market Size and Growth Rate (2021-2030) Figure Musculoskeletal Market Size and Growth Rate (2021-2030) Figure Immunology & Inflammation Market Size and Growth Rate (2021-2030) Table United States Regenerative Medicine Market by Regions (2023-2030) Figure North America United States Regenerative Medicine Market Size and Growth Rate (2021-2030)
Research Methodology
The process of market research at Ultra Market Research is an iterative in application and usually follows following path. Information from secondary used to build data models, then results from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done and new Information is again incorporated into data model. The process continues till desired level of Information is not generated
To calculate the market size, the report considers the revenue generated from the sales of Ultra Market Research providers. The revenue generated from the sales of Ultra Market Research has been calculated through primary and secondary research. The report also presents the key players operating in the Ultra Market Research market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes distribution channel segmentation determined using secondary sources and verified through primary sources.
Secondary Research
The secondary research source that are typically referred to include, but are not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
Internal and external proprietary databases, relevant patent and regulatory databases
National government documents, statistical databases and market reports
News articles, press releases and web-casts specific to the companies operating in the market
The source for secondary research includes but is not limited to: Factiva, Hoovers and Statista
Inner Circle Represents – Stage of Research Process
Middle Circle Represents – Source of Information
Outer Circle Represents – Information Derived from that source
Primary Research We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:
It provides first-hand Information on the market size, market trends, growth trends, competitive landscape, future outlook etc.
Helps in validating and strengthening the secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies
The participants who typically take part in such a process include, but are not limited to:
Industry participants: CEOs, VPs, marketing/ distribution channel managers, market intelligence managers and national sales managers
Purchasing managers, technical personnel, distributors and resellers
Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry distribution channels
Models Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data distribution channels to produce estimates:
Demographic data: Population split by segment
Macro-economic indicators: GDP, etc.
Industry indicators: Expenditure, distribution channel stage & infrastructure, sector growth and facilities.
Data is then cross checked by the expert panel.
2..1 Company Share Analysis Model
Company share analysis is used to derive the size of Global market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps: 2..2 Revenue Based Modeling
Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach.
2.1 Research Limitations Inflation is not a part of pricing in this report. Prices of Allogeneic Cell Therapy Devices Market and its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each distribution channel has been taken into account while estimating and forecasting market revenue Globally. Regional average price has been considered while breaking down this market by application in each region. This report provides market size of Global Allogeneic Cell Therapy Devices Market for the past year and forecasts for the next six years. Global Allogeneic Cell Therapy Devices Market. Market size is given in terms of revenue. Market revenue is defined in USD Million. Market numbers are given on the basis of different Allogeneic Cell Therapy Devices Market categories. Market size and forecasts for each major application is provided in the context of Global market. The numbers provided in this report are derived on the basis of demand for Allogeneic Cell Therapy Devices Market from different application industries in different regions.
